MYIA
TGTX icon

Mount Yale Investment Advisors’s TG Therapeutics TGTX Stock Holding History

Mount Yale Investment Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-570
Closed -$20.5K – 1512
2025
Q2 		$20.5K Buy
+570
New +$21.2K ﹤0.01% 1035

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mount Yale Investment Advisors's TGTX Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 570 shares — an estimated $20.5K sold.

Mount Yale Investment Advisors first reported a position in TGTX in Q2 2025 and held it in 1 quarter. The position peaked at $20.5K in Q2 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • Mount Yale Investment Advisors reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 570 TG Therapeutics shares in Q3 2025, an estimated $20.5K.
  • Mount Yale Investment Advisors first reported a position in TG Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mount Yale Investment Advisors's TG Therapeutics position peaked at $20.5K in Q2 2025.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.